Immuron Letter to Shareholders: Projects Update

Sales Performance - Immuron achieved record sales of A$7 million for the current financial year, a significant increase from A$4.9 million in the previous year [3][10] - Sales momentum continued into April, driven by holiday periods and seasonal breaks in North America [3] Clinical Trial Updates - Immuron is developing three therapeutic products: IMM-124E for traveler's diarrhea, IMM-529 for Clostridioides difficile infection, and IMM-986 for Vancomycin-resistant enterococci [4] - Recruitment for the IMM-124E field study has been completed, with topline results expected in October 2025 [5][10] - The company plans to request an end of Phase 2 meeting with the FDA for IMM-124E, with projected annual revenue in the USA estimated at US$102 million [6] - IMM-529 is progressing towards an IND submission to the FDA, anticipated in August 2025, with peak revenues projected at approximately US$400 million [7][8] Product Launch Plans - Immuron is preparing to launch ProIBS® in Australia, with a product delivery expected in Q3 2025 and launch in Q1 2026 [11][10] - The IBS treatment market in Australia is projected to generate around A$221 million in 2025, with an annual growth rate of 3.28% [11] Pre-clinical Research - Immuron is collaborating with Monash University on IMM-986, targeting Vancomycin-resistant enterococci, with pre-clinical research results expected in August 2025 [12][10] - The estimated national cost to treat infections from antimicrobial resistance in the U.S. exceeds $4.6 billion annually [12]